Nastech to host free Web cast on emerging RNAi programs and technology

Nastech Pharmaceutical Company Inc.

TO MEDICAL/SCIENCE/HEALTH/BUSINESS JOURNALISTS AND EDITORS:

Webcast Alert: Nastech to Host free Webcast on emerging RNAi Programs and Technology on November 9, 2006, at 10:30 AM U.S. East Coast time

What: RNAi webinar on the science and business of RNAi therapeutics followed by a Q&A session. Questions may be emailed in advance to rnaiwebinar@nastech.com or during the event through the webinar interface (your anonymity on the Q&A is assured)

When: Thursday, November 9, 2006, at 10:30-11:15 AM U.S. East Coast time

How: Live over the Internet via a simple advanced registration at http://www.talkpoint.com/viewer/starthere.asp?Pres=114985

Where: Webinar will be available at http://www.talkpoint.com/viewer/presentation.asp once you are registered

Contact: Matthew Haines of Noonan Russo at 212-845-4235 or matthew.haines@eurorscg.com.

If you are unable to participate during the live RNAi webinar webcast, an archive and replay will be available for 30 days via Nastech's website at http://investor.nastech.com/phoenix.zhtml?c=83674&p=irol-calendar

###

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK; http://www.nastech.com) is an emerging leader in the development of RNAi therapeutics. Key developments in Nastech's RNAi program are:
9/26/06 - Nastech Receives $1.9 Million National Institute of Health-R01 Grant for Development of RNAi Therapeutics to Prevent and Treat Influenza
8/29/06 - Nastech Awarded Development Grant for RNAi Therapeutics to Prevent and Treat Influenza
3/16/06 - Nastech Presents Successful In Vitro and In Vivo Results with Its RNAi Therapeutics Program for Influenza
2/23/06 - Nastech Acquires RNAi Therapeutics Program Targeting Influenza from Galenea
11/17/05 - Nastech Presents Positive Results on RNA Interference Program for Treatment of Rheumatoid Arthritis at the American College of Rheumatology Annual Scientific Meeting
7/20/05 - Alnylam Grants Nastech a License to Develop RNAi Therapeutics Against TNF-alpha
4/5/05 - Nastech Announces RNAi Therapeutics-Based Rheumatoid Arthritis Clinical Study Collaboration
4/5/05 - Nastech presents promising In Vivo research findings with RNAi-Based Therapeutics for Rheumatoid Arthritis at the 2005 American Society for Biochemistry and Molecular Biology Annual Meeting
2/2/04 - Nastech obtains a non-exclusive license from the Carnegie Institute of Washington, D.C. to the Fire et al patents and patent applications titled "Genetic Inhibition by Double-Stranded RNA" (including U.S. Patent # 6,506,559 B1)


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

Consistency is the last refuge of the unimaginative.
-- Oscar Wilde